Hepatitis C

Nontargeted screening identified more HCV infections than targeted screening, but both approaches led to minimal linkage to care and SVR12.

The first half of 2025 recap for hepatology spotlights FDA approvals, clinical trial updates, and the 1-year anniversary of resmetirom.

The Q2 recap for hepatology spotlights regulatory approvals, clinical trial updates, and the launch of HCPLive’s flagship hepatology podcast.

The month in review spotlights hepatic regulatory news, new clinical trial data, and novel research about liver disease risk factors.

Topline data from the phase 1b study for the final 400 mg dose cohort demonstrate favorable safety, tolerability, and pharmacokinetics similar to the 150 mg dose cohort.

While achieving SVR was linked to improvements in fibrosis markers, hepatic steatosis prevalence increased, especially in those with metabolic dysfunctions.

Successful HCV treatment with DAAs was associated with reduced risks of CKD, stroke, major adverse cardiac events, and neurocognitive disorders.

The label expansion makes glecaprevir/pibrentasvir the first and only oral 8-week pangenotypic treatment option approved for people with acute or chronic HCV.

The month in review spotlights hepatic podcast episodes from HCPLive, new clinical trial data, and coverage from DDW.

Hosts Kimberly Brown and Nancy Reau break down 4 of the top abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress.

Gyre Therapeutics plans to file an NDA in China based on the phase 3 CHB data and, pending IND clearance, is looking to initiate a phase 2 MASH fibrosis trial in the US.

Phase 4 trial results showed switching to BSV after long-term TDF was noninferior for antiviral efficacy and led to improved kidney function and bone density.

Our Q1 recap for hepatology spotlights regulatory updates, clinical trial data, 2 new guidance documents, and the anniversary of a historic FDA approval.

The month in review spotlights coverage of the anniversary of resmetirom’s FDA approval and research in autoimmune hepatitis, HBV vaccination, and MASLD.

The success of community-based point-of-diagnosis HCV treatment in the NOW trial was attributable to collaborative care with an integrated pharmacy team.

Maternal vaccination during pregnancy with the Tdap or seasonal influenza vaccine was associated with greater odds of newborn receipt of the HepB vaccine.

The hepatology month in review spotlights HCPLive’s coverage of hepatic drug development and research about GLP-1 RAs, viral hepatitis, and MASH.

HCV screening in pregnant women increased following universal screening guidelines, but the proportion of women who were ever tested remained low.

HDV RNA-positive patients were more often diagnosed with advanced liver fibrosis and had a 4.7-fold greater risk of severe liver-related outcomes.

Younger age, low knowledge of HBV sequelae, and high perceived HBV stigma were linked to lower medication adherence in Korean American patients.

In patients with HCV-related compensated cirrhosis, DAA treatment was linked to lower HCC risk than no treatment but similar risk to a historical IFN cohort.

Findings suggest the value of genotyping and histological assessment for guiding HCC screening decisions in patients with chronic HBV.

Findings suggest MASLD, especially with diabetes, overweight, or hypertension, is associated with significant fibrosis in patients with HCV.

The updated clinical practice guideline addresses new research and clinical developments since the first iteration of the guideline was released in 2014.

The Breakthrough Therapy designation comes just months after positive phase 2 data for brelovitug were presented at AASLD The Liver Meeting in 2024.